Silence Therapeutics' (SLN) Buy Rating Reiterated at HC Wainwright

Silence Therapeutics (NASDAQ:SLN - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $75.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 490.55% from the company's previous close.

A number of other analysts also recently commented on SLN. Jefferies Financial Group started coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They set a "buy" rating and a $40.00 price target for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Finally, Chardan Capital reissued a "buy" rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Thursday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $57.20.

Silence Therapeutics Trading Down 9.2 %

NASDAQ:SLN traded down $1.28 during mid-day trading on Friday, hitting $12.70. 438,712 shares of the company's stock were exchanged, compared to its average volume of 202,369. Silence Therapeutics has a fifty-two week low of $8.94 and a fifty-two week high of $27.72. The company has a 50 day simple moving average of $17.98 and a 200-day simple moving average of $19.14. The firm has a market capitalization of $380.09 million, a P/E ratio of -8.09 and a beta of 1.30.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $11.28 million. As a group, analysts expect that Silence Therapeutics will post -1.55 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

A number of large investors have recently modified their holdings of the business. Values First Advisors Inc. bought a new position in Silence Therapeutics in the third quarter valued at $56,000. Quarry LP purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $114,000. SG Americas Securities LLC lifted its position in Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company's stock worth $151,000 after buying an additional 667 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Silence Therapeutics in the third quarter worth approximately $207,000. Finally, Custom Index Systems LLC bought a new position in Silence Therapeutics during the second quarter valued at approximately $282,000. Institutional investors own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.